Claims for Patent: 6,716,830
✉ Email this page to a colleague
Summary for Patent: 6,716,830
| Title: | Ophthalmic antibiotic compositions containing moxifloxacin |
| Abstract: | Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues. |
| Inventor(s): | Cagle; Gerald (Fort Worth, TX), Abshire; Robert L. (Fort Worth, TX), Stroman; David W. (Irving, TX), Yanni; John M. (Burleson, TX) |
| Assignee: | Alcon, Inc. (Hunenberg, CH) |
| Application Number: | 10/200,868 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,716,830 |
| Patent Claims: |
1. A topical ophthalmic pharmaceutical composition comprising moxifloxacin or a pharmaceutically useful hydrate or salt thereof in a concentration of 0.1 to 1.0 wt % and
pharmaceutically acceptable vehicle therefor.
2. An ophthalmic composition according to claim 1, wherein the composition further comprises an anti-inflammatory effective amount of a steroidal or non-steroidal glucocorticoid. 3. An ophthalmic composition according to claim 2, wherein the anti-inflammatory agent comprises a steroidal agent. 4. An ophthalmic composition according to claim 3, wherein the steroidal agent comprises a glucocorticoid. 5. An ophthalmic composition according to claim 4, wherein the glucocorticoid is selected from the group consisting of dexamethasone, rimexolone, prednisolone, fluorometholone, hydrocortisone, mometasone, fluticasone, beclomethasone, flunisolide, triamcinolone and budesonide. 6. An ophthalmic composition according to claim 4, wherein the glucocorticoid comprises dexamethasone. 7. An ophthalmic composition according to claim 4, wherein the glucocorticoid comprises a 21-ether derivative of dexamethasone. 8. An ophthalmic composition according to claim 4, wherein the glucocorticoid comprises a 21-benzyl ether derivative of dexamethasone. 9. An ophthalmic composition according to claim 2, wherein the anti-inflammatory agent comprises a non-steroidal agent selected from the group consisting of prostaglandin H synthetase inhibitors, cyclooxygenase type II selective inhibitors, PAF antagonists, and PDE IV inhibitors. 10. An ophthalmic composition according to claim 9, wherein the non-steroidal agent comprises a prostaglandin H synthetase inhibitor. 11. An ophthalmic composition according to claim 10, wherein the prostaglandin H synthetase inhibitor comprises nepafenac. 12. An ophthalmic composition according to claim 10, wherein the prostaglandin H synthetase inhibitor comprises ketorolac. 13. An ophthalmic composition according to claim 10, wherein the prostaglandin H synthetase inhibitor comprises diclofenac. 14. An ophthalmic composition according to claim 9, wherein the non-steroidal agent comprises a cyclooxygenase type II selective inhibitor. |
